Cargando…
Case Report: Apremilast for Therapy-Resistant Pemphigus Vulgaris
BACKGROUND: In pemphigus, elucidating the disease-causing immune mechanism and developing new therapeutic strategies are needed. In this context, the second messenger 3′,5′-cyclic adenosine monophosphate (cAMP) is gaining attention. cAMP is important in hematological and auto-inflammatory disorders....
Autores principales: | Meier, Katharina, Holstein, Julia, Solimani, Farzan, Waschke, Jens, Ghoreschi, Kamran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7653172/ https://www.ncbi.nlm.nih.gov/pubmed/33193415 http://dx.doi.org/10.3389/fimmu.2020.588315 |
Ejemplares similares
-
Detection of rare autoreactive T cell subsets in patients with pemphigus vulgaris
por: Polakova, Alexandra, et al.
Publicado: (2022) -
Dsg1 and Dsg3 Composition of Desmosomes Across Human Epidermis and Alterations in Pemphigus Vulgaris Patient Skin
por: Schmitt, Thomas, et al.
Publicado: (2022) -
Pemphigus Foliaceus Autoantibodies Induce Redistribution Primarily of Extradesmosomal Desmoglein 1 in the Cell Membrane
por: Hiermaier, Matthias, et al.
Publicado: (2022) -
Emerging Topical and Systemic JAK Inhibitors in Dermatology
por: Solimani, Farzan, et al.
Publicado: (2019) -
Janus kinase signaling as risk factor and therapeutic target for severe SARS‐CoV‐2 infection
por: Solimani, Farzan, et al.
Publicado: (2021)